Aspira Pathlab & Diagnostics Approves ₹65 Crore Rights Issue Subject To Approvals

Board approved fundraise of up to Rs 65 Cr via rights issue to eligible shareholders as on record date, in equity or convertibles, subject to approvals. Formed Rights Issue Committee. Revives fundraise deferred at prior board meeting within weeks; first equity dilution after years without dilution and first large raise under new promoter control, a step change in funding approach. Price, ratio, record date, use of proceeds and timeline left to committee and approvals; size implies heavy dilution for small cash-light base; funding rationale not disclosed.